
    
      This will be a Phase 1/2, double-blind, randomized, placebo-controlled, dose-escalation study
      conducted at a single center for the healthy volunteer cohorts in up to 56 participants. It
      will consist of 1 single-dose cohort and 3 multiple-dose cohorts (n = 12 per cohort, 10
      active:2 placebo). The open-label, hATTR patient cohort portion of the study will be
      conducted at multiple centers.
    
  